Circadian is to trade shares for the remaining third of Vegenics

Finnish research finds new role for VEGFR-3 in angiogenesis

New centre for imaging and medical therapy being built at the Australian Synchrotron.

Two major projects to study colorectal cancer and HIV/AIDS were the big winners in the NHMRC grants round.

Fish is brain food and for most of us that means eating it. For Michael Lardelli, zebrafish are also helping us understand the human brain.

Australian biotech companies EvoGenix and Vegenics have entered into a technology collaboration agreement to target vascular endothelial growth factor D (VEGF-D), a mediator in angiogenesis.

Angiogenesis inhibition is not enough - blocking the formation of new lymphatic vessels is vital to preventing secondary tumours.

Melbourne's Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has in-licensed patents from the Ludwig Institute for Cancer Research for antibodies that target a key part of the inflammatory process.

The Victorian government has pledged $26.6 million in infrastructure funding to 17 independent medical research institutes in the state.

Susan Williamson discovers why the theme of tissue architecture is so prominent at this year's Lorne Cancer conference.

Amrad (ASX:AML) and the Ludwig Institute for Cancer Research have strengthened their collaboration for the development of vascular endothelial growth factor B (VEGF-B), which has potential applications in cancer and cardiovascular disease.